within Pharmacolibrary.Drugs.ATC.A;

model A02BC08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.0003133333333333333,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.168,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 16.8
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BC08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD) and peptic ulcer. It is approved and used in various countries for gastric acid suppression.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical pharmacokinetics</i> 55(4) 409–418. DOI:<a href=\"https://doi.org/10.1007/s40262-015-0326-7\">10.1007/s40262-015-0326-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26369775/\">https://pubmed.ncbi.nlm.nih.gov/26369775</a></p></li><li><p>Shen, J, et al., &amp; Liu, B (2020). Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats. <i>Drug design, development and therapy</i> 14 2199–2206. DOI:<a href=\"https://doi.org/10.2147/DDDT.S255427\">10.2147/DDDT.S255427</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32581516/\">https://pubmed.ncbi.nlm.nih.gov/32581516</a></p></li><li><p>Kong, WM, et al., &amp; Liu, XD (2020). Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans. <i>Acta pharmacologica Sinica</i> 41(6) 852–865. DOI:<a href=\"https://doi.org/10.1038/s41401-019-0353-2\">10.1038/s41401-019-0353-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31969689/\">https://pubmed.ncbi.nlm.nih.gov/31969689</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BC08;
